ATE220921T1 - Bifunktionelle glykoproteine mit modiziertem karbohydratkomplement und deren anwendung in der tumorselektiven therapie - Google Patents

Bifunktionelle glykoproteine mit modiziertem karbohydratkomplement und deren anwendung in der tumorselektiven therapie

Info

Publication number
ATE220921T1
ATE220921T1 AT94106394T AT94106394T ATE220921T1 AT E220921 T1 ATE220921 T1 AT E220921T1 AT 94106394 T AT94106394 T AT 94106394T AT 94106394 T AT94106394 T AT 94106394T AT E220921 T1 ATE220921 T1 AT E220921T1
Authority
AT
Austria
Prior art keywords
glycoproteins
bifunctional
tumor
carbohydrate complement
application
Prior art date
Application number
AT94106394T
Other languages
English (en)
Inventor
Klaus Dr Bosslet
Joerg Dr Czech
Dieter Dr Hoffmann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE220921T1 publication Critical patent/ATE220921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT94106394T 1993-05-04 1994-04-25 Bifunktionelle glykoproteine mit modiziertem karbohydratkomplement und deren anwendung in der tumorselektiven therapie ATE220921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4314556A DE4314556A1 (de) 1993-05-04 1993-05-04 Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie

Publications (1)

Publication Number Publication Date
ATE220921T1 true ATE220921T1 (de) 2002-08-15

Family

ID=6487030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94106394T ATE220921T1 (de) 1993-05-04 1994-04-25 Bifunktionelle glykoproteine mit modiziertem karbohydratkomplement und deren anwendung in der tumorselektiven therapie

Country Status (11)

Country Link
US (1) US8552159B2 (de)
EP (1) EP0623352B1 (de)
JP (1) JPH06319554A (de)
KR (1) KR100387452B1 (de)
AT (1) ATE220921T1 (de)
AU (1) AU684750B2 (de)
CA (1) CA2122745C (de)
DE (2) DE4314556A1 (de)
DK (1) DK0623352T3 (de)
ES (1) ES2177554T3 (de)
PT (1) PT623352E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1500400A4 (de) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Arzneimittel mit antikörper-zusammensetzung
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
KR101540319B1 (ko) * 2013-10-01 2015-07-30 한국생명공학연구원 cyb5R3 유전자 또는 단백질을 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU656181B2 (en) * 1991-05-03 1995-01-27 Pasteur Sanofi Diagnostics Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung

Also Published As

Publication number Publication date
US8552159B2 (en) 2013-10-08
DE69431018T2 (de) 2003-02-27
CA2122745C (en) 2010-06-22
DE4314556A1 (de) 1994-11-10
KR100387452B1 (ko) 2003-11-13
US20040202646A1 (en) 2004-10-14
PT623352E (pt) 2002-12-31
ES2177554T3 (es) 2002-12-16
DK0623352T3 (da) 2002-11-11
EP0623352A3 (de) 1995-02-22
CA2122745A1 (en) 1994-11-05
EP0623352A2 (de) 1994-11-09
AU6182994A (en) 1994-11-10
JPH06319554A (ja) 1994-11-22
EP0623352B1 (de) 2002-07-24
DE69431018D1 (de) 2002-08-29
AU684750B2 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
BR9915164A (pt) Tratamento de malignidades hematológicas associadas com células de tumor circulantes usando anticorpo anti-cd20 quimérico
SG52383A1 (en) Compositions comprising complement related proteins and carbohydrates and methods for producing and using said compositions
IL88428A0 (en) Anti-tumor drug-monoclonal antibody conjugates
PT910382E (pt) Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
PH24313A (en) Emulsion composition for administration of sparingly water soluble ionizable hydrophobic drugs
NL191308C (nl) Gelyofiliseerd, na oplossing injecteerbaar preparaat dat een antracycline-glycoside bevat, alsmede werkwijze voor de bereiding van een injecteerbare oplossing van een antracycline-glycoside.
EE200000039A (et) MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine
SE8402560L (sv) Farmaceutisk komposition
DE68912334D1 (de) Immunokonjugate für krebs-diagnose und -therapie.
ZA951295B (en) 6-substituted mycophenolic acid and derivatives
ATE220921T1 (de) Bifunktionelle glykoproteine mit modiziertem karbohydratkomplement und deren anwendung in der tumorselektiven therapie
BG42837A3 (bg) Метод за получаване на имуноглобулинови производни на винка алкалоиди
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
ATE222124T1 (de) Chemische mittel
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
BR8905657A (pt) Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica
ATE254481T1 (de) Radioaktiven chitosankomplex und deren anwendung in strahlungstherapie
EP0173663A3 (en) The use of a specific tumor associated antigen, sialosyllactotetraose, in diagnostic or therapeutic procedures related to cancer deseases
PT95620A (pt) Processo para a preparacao de pro-drogas glicosil-etoposido e de composicoes farmaceuticas que as contem em combinacao com conjugados de enzima especificos para tumor funcionalizados
OA09439A (fr) "Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent".
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
ATE240108T1 (de) Doxorubicin enthaltende einspritzbare gebrauchsfertige lösungen gegen krebs
PT938900E (pt) Profilaticos/medicamentos para estomatite

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification